Acadia Pharmaceuticals (ACAD) Total Liabilities (2010 - 2026)

Acadia Pharmaceuticals' Total Liabilities history runs 17 years deep, the most recent figure standing at $357.2 million for Q1 2026.

• On a quarterly basis, Total Liabilities fell 2.71% year-over-year to $357.2 million in Q1 2026; TTM through Mar 2026 was $357.2 million, a 2.71% decrease from a year earlier, with the FY2025 full-year figure at $336.8 million, down 25.97% from the prior year.
• Total Liabilities advanced to $357.2 million in Q1 2026 per ACAD's latest filing, from $336.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $455.0 million in Q4 2024 and bottomed at $176.8 million in Q3 2022.
• The 5-year median for Total Liabilities is $336.8 million (2025), against an average of $315.2 million.
• Across the five-year window, Total Liabilities jumped 69.27% in 2023 and declined 25.97% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $187.4 million in 2022, then soared by 69.27% to $317.2 million in 2023, then soared by 43.43% to $455.0 million in 2024, then fell by 25.97% to $336.8 million in 2025, then grew by 6.04% to $357.2 million in 2026.
• Per Business Quant, the three latest ACAD Total Liabilities figures stand at $357.2 million (Q1 2026), $336.8 million (Q4 2025), and $413.5 million (Q3 2025).